PHASEBIO PHARMACEUTICALS INC's ticker is PHAS and the CUSIP is 717224109. A total of 50 filers reported holding PHASEBIO PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $14,000 | -70.2% | 79 | 0.0% | 0.00% | – |
| Q2 2022 | $47,000 | -54.8% | 79 | 0.0% | 0.00% | – |
| Q1 2022 | $104,000 | -49.5% | 79 | 0.0% | 0.00% | – |
| Q4 2021 | $206,000 | -82.6% | 79 | -79.2% | 0.00% | – |
| Q3 2021 | $1,182,000 | +5.5% | 380 | +26.2% | 0.00% | – |
| Q2 2021 | $1,120,000 | -86.0% | 301 | -87.0% | 0.00% | – |
| Q1 2021 | $8,020,000 | -26.3% | 2,318 | -28.4% | 0.00% | – |
| Q4 2020 | $10,883,000 | -8.1% | 3,239 | -4.0% | 0.00% | – |
| Q3 2020 | $11,843,000 | +214.0% | 3,374 | +311.5% | 0.00% | – |
| Q2 2020 | $3,772,000 | -73.0% | 820 | -80.6% | 0.00% | – |
| Q1 2020 | $13,981,000 | +21.1% | 4,224 | +123.5% | 0.00% | – |
| Q4 2019 | $11,548,000 | +59.8% | 1,890 | +9.1% | 0.00% | – |
| Q3 2019 | $7,227,000 | +1474.5% | 1,733 | +4851.4% | 0.00% | – |
| Q2 2019 | $459,000 | – | 35 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 1,607,044 | $4,194,000 | 0.48% |
| NEA Management Company, LLC | 6,643,704 | $17,340,000 | 0.35% |
| Platform Technology Partners | 251,723 | $657,000 | 0.29% |
| DAFNA Capital Management LLC | 378,611 | $988,000 | 0.25% |
| Avidity Partners Management LP | 4,405,000 | $11,497,000 | 0.24% |
| Endurant Capital Management LP | 360,078 | $940,000 | 0.23% |
| Rock Springs Capital Management LP | 2,581,299 | $6,737,000 | 0.16% |
| RA Capital Management | 2,850,000 | $7,439,000 | 0.13% |
| New Legacy Group, LLC | 240,575 | $628,000 | 0.12% |
| XTX Topco Ltd | 15,574 | $41,000 | 0.02% |